|Toxiciy Grade:||4||City/State/Province:||Durham, N.C.|
|Treatments:||Chemotherapy||Hospital:||Duke University Medical Center|
Patients: This Phase II study involved 32 adult patients with recurrent glioblastoma multiforme. The median age of the patients was 56 years, ranging from 33-79 years. All had received prior radiation therapy. The majority of patients (75%) were men.
Treatment: All patients received the chemotherapy Cloretazine once every six weeks.
Toxicity: The most common toxicities were thrombocytopenia (in 19% of patients at a Grade 3 level, in 28% of patients at a Grade 4 level). The other most common Grade 3 and 4 toxicities were neutropenia.
Results: The authors do not report the median overall survival time. The median progression free survival time was 6.3 weeks. Of the 32 patients enrolled in this study, 31 eventually developed progressive disease. The authors concluded that "in this patient population...there were no objective radiographic responses to Cloretazine, although two patients had minor responses."
Support: One author is employed by Vion Pharmaceuticals, which supplied the Cloretazine used in this study.
Correspondence: James Vredenburgh, M.D.